December 2016 Vol 9, Special Issue: Payers’ Perspectives In Oncology: AVBCC 2016 Highlights - Immunotherapy
Washington, DC—The Cancer Moonshot 2020 program is exploring a new paradigm in cancer care by bringing clinical trials focused on immunotherapy to community and academic practices. This privately funded initiative seeks to conduct phase 2 clinical trials within the next 36 months in 20,000 patients with >20 tumor types at all stages of cancer, said Gary Palmer, MD, JD, MPH, Chief Medical Officer, President, GPS Operations, NantHealth, Culver City, CA, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Oncologists looking to learn about immunotherapy did not have to go very far at ASCO 2015. Many of the highest-impact presentations this year, including a plenary session, the Karnofsky Award, and the Science of Oncology Award, focused on cancer therapy’s most exciting field.
Combination treatment with the 2 immunotherapies nivolumab and ipilimumab led to a doubling in progression-free survival (PFS) compared with ipilimumab alone in patients with advanced melanoma,
Results 1 - 3 of 3